MiRNAs Evaluate the Prognosis of Sepsis

Sepsis Clinical Trial

— METPS  

Official title:

miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01207531
• Other study ID #: 301PLAGH-2010915
• Status: Recruiting
• Phase: N/A
• First received: September 17, 2010
• Last updated: September 22, 2010
• Start date: July 2010
• Est. completion date: April 2011

Study information

• Verified date: September 2010
• Source: Chinese PLA General Hospital
• Contact: Huijuan Wang, master
• Phone: +86 13466791738
• Email: wanghuijuan301[@]gmail.com
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Observational

Clinical Trial Summary

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.

Description:

The study is a non-intervention, prospective observational study. Purpose of this sudy is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis . We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009 , and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: April 2011
• Est. primary completion date: November 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of sepsis

• Patients who agree with the study

Exclusion Criteria:

• Aged <18 years;

• Into the group who died within 24 hours;

• Agranulocytosis (<0.5 × 109 / L);

• Combined HIV infection.

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Sepsis
• Toxemia

Locations

Country	Name	City	State
China	Chinese PLA General Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	all cause mortality		28days after admited in ICU	No